4Pharma - Beyond Your Data

Especially lively summer in the scientific publications front at 4Pharma


Especially lively summer in the scientific publications front at 4Pharma

This summer in 4Pharma has been exceptionally vivid regarding scientific publications. The results of several trials / analyses where 4Pharma has had the privilege to contribute were published in scientific journals: These papers nicely show how variant are the fields of research where 4Pharma operates. Below are short summaries of the publications released this summer:

A registry-based study regarding medication adherence and persistence among 7474 adult MS-patients in Finland by Lahdenperä et al (including Junnila J). The objective of the study was to explore adherence, persistence, and treatment patterns in patients with treated with disease‐modifying therapies (DMTs) for active MS in 2005‐2018. https://onlinelibrary.wiley.com/doi/abs/10.1111/ane.13301.

A phase II study on esophageal cancer (LEOPARD II) by Rades et al (including Männikkö S). The objective of the study was to investigate the efficacy and toxicity of cetuximab when added to radiochemotherapy for unresectable esophageal cancer. Based on the 2-year overall survival rates (Median OS 49.1 months with radiochemotherapy plus cetuximab compared to 24.1 months with radiochemotherapy only), the combination treatment was deemed promising for further investigation. https://link.springer.com/article/10.1007/s00066-020-01646-4

A bioavailability study (regarding dietary management of patients with phenylketonuria (PKU) by Scheinin et al (including Junnila J). The principal aim of this bioavailability study was to demonstrate that the absorption profile of Amino acids from APR-1301-01 modified-release AA mixture into the bloodstream was different from that observed with an immediate-release free AA mixture. The study reached both it’s co-primary endpoints: https://www.mdpi.com/2072-6643/12/6/1653

A scientific letter by Jalkanen et al (including Huttunen T) regarding glucocorticoids usage in treating acute respiratory distress syndrome (ARDS). This post-hoc statistical analysis of the INTEREST-trial showed that Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung: https://link.springer.com/article/10.1007%2Fs00134-020-06086-3

An observational study on Recovery of Vaginal Microbiota after Standard Treatment for Bacterial Vaginosis Infection by Lehtoranta et al (including Junnila J). The study showed that Vaginal microbiota of women with BV shifted to resemble that of healthy controls after metronidazole treatment: https://www.mdpi.com/2076-2607/8/6/875

A cross-over study by Turunen et al (including Männikkö S) to investigate the impact of intramuscular co-administration of the peripheral α2-adrenoceptor agonist vatinoxan (MK-467) with medetomidine and butorphanol prior to intravenous ketamine on the cardiopulmonary and anaesthetic effects in dogs, followed by atipamezole reversal: https://www.vaajournal.org/article/S1467-2987(20)30105-7/pdf

In addition to these articles, our biostatistician Parisa Hariri has published a book regarding Conformally Invariant Metrics and Quasiconformal Mappings. In her book Parisa gives an introduction to the theory of quasiconformal and quasiregular mappings in the euclidean n-dimensional space, (where n is greater than 2). https://www.springer.com/gp/book/9783030320676#aboutBook